Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 36,856 shares at $16.26 ($599K) on 2025-09-02, disclosed to the SEC on 2025-09-03.
Open-market sale of $599k SYRE by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.26 | 18,428 | $300K | 50.0% |
| 2 | $16.26 | 18,428 | $300K | 50.0% |
| Total | $16.26 avg | 36,856 | $599K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |